Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer by Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Genichiro Ishii, Kohei Shitara

Get full text